Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:CASI NASDAQ:CDT NASDAQ:KPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.86+2.0%$0.82$0.55▼$2.22$10.65M1.481.73 million shs159,052 shsCASICASI Pharmaceuticals$0.21$0.23$0.21▼$3.09$2.55M0.91482,532 shsN/ACDTCDT Equity$2.21+6.3%$9.11$2.05▼$1,425.00$10.84M1.667,859 shs13,704 shsKPRXKiora Pharmaceuticals$2.52+0.3%$2.19$1.76▼$4.18$11.16M-0.48374,505 shs15,782 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+3.08%+0.75%+17.86%+25.85%-51.82%CASICASI Pharmaceuticals0.00%0.00%0.00%-77.98%-89.16%CDTCDT Equity-7.96%-15.45%-47.34%-92.15%-99.86%KPRXKiora Pharmaceuticals+2.87%+7.73%+29.38%+14.61%-23.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.86+2.0%$0.82$0.55▼$2.22$10.65M1.481.73 million shs159,052 shsCASICASI Pharmaceuticals$0.21$0.23$0.21▼$3.09$2.55M0.91482,532 shsN/ACDTCDT Equity$2.21+6.3%$9.11$2.05▼$1,425.00$10.84M1.667,859 shs13,704 shsKPRXKiora Pharmaceuticals$2.52+0.3%$2.19$1.76▼$4.18$11.16M-0.48374,505 shs15,782 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+3.08%+0.75%+17.86%+25.85%-51.82%CASICASI Pharmaceuticals0.00%0.00%0.00%-77.98%-89.16%CDTCDT Equity-7.96%-15.45%-47.34%-92.15%-99.86%KPRXKiora Pharmaceuticals+2.87%+7.73%+29.38%+14.61%-23.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.25Hold$4.10376.74% UpsideCASICASI Pharmaceuticals 2.00Hold$4.001,827.71% UpsideCDTCDT Equity 1.00SellN/AN/AKPRXKiora Pharmaceuticals 2.00Hold$10.00297.14% UpsideCurrent Analyst Ratings BreakdownLatest CASI, CDT, APRE, and KPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026KPRXKiora Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/31/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.003/31/2026APREAprea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $1.203/27/2026CDTCDT Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)2/16/2026APREAprea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold2/10/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$11.00 ➝ $7.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K36.71N/AN/A$1.52 per share0.57CASICASI Pharmaceuticals$26.85M0.10N/AN/A$0.12 per share1.73CDTCDT EquityN/AN/AN/AN/A($77.82) per shareN/AKPRXKiora Pharmaceuticals$16.02M0.70N/AN/A$4.38 per share0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.98N/AN/AN/A-4,405.59%-96.33%-74.35%5/13/2026 (Estimated)CASICASI Pharmaceuticals-$39.26M-$3.01N/AN/AN/A-183.93%N/A-131.54%N/ACDTCDT Equity-$39.22M-$66,338.55N/AN/AN/AN/A-4,263.33%-529.91%N/AKPRXKiora Pharmaceuticals-$10.84M-$2.65N/AN/AN/AN/A-51.37%-36.09%5/8/2026 (Estimated)Latest CASI, CDT, APRE, and KPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026APREAprea Therapeutics-$0.22N/AN/AN/A$0.00 millionN/A5/8/2026Q1 2026KPRXKiora Pharmaceuticals-$0.71N/AN/AN/A$1.50 millionN/A3/25/2026Q4 2025KPRXKiora Pharmaceuticals-$0.70-$1.60-$0.90-$1.60$1.50 millionN/A3/16/2026Q4 2025APREAprea Therapeutics-$0.38-$0.32+$0.06-$0.32N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACASICASI PharmaceuticalsN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.635.63CASICASI PharmaceuticalsN/A0.300.24CDTCDT EquityN/A0.340.34KPRXKiora PharmaceuticalsN/A5.995.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CASICASI Pharmaceuticals22.23%CDTCDT Equity3.29%KPRXKiora Pharmaceuticals76.97%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%CASICASI Pharmaceuticals21.24%CDTCDT Equity10.78%KPRXKiora Pharmaceuticals0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million10.35 millionNo DataCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableCDTCDT Equity34.86 million4.33 millionNot OptionableKPRXKiora Pharmaceuticals104.43 million3.95 millionNot OptionableCASI, CDT, APRE, and KPRX HeadlinesRecent News About These CompaniesKiora Pharmaceuticals (KPRX) Projected to Post Quarterly Earnings on FridayMay 1, 2026 | americanbankingnews.comKiora’s phase 1 ABACUS study of KIO-301 in retinitis pigmentosa published in Nature Medicine; phase 2 trial underwayApril 15, 2026 | eurekalert.orgEKiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial UnderwayApril 14, 2026 | newsfilecorp.comNKiora's KIO-301 Study in Retinitis Published, Phase 2 OnApril 14, 2026 | miragenews.comMWhy did KPRX stock surge 17% pre-market today?April 7, 2026 | msn.comKiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive AdvisorsApril 7, 2026 | finance.yahoo.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive AdvisorsApril 7, 2026 | finanznachrichten.deKiora Pharmaceuticals Announces Chief Development Officer ResignationApril 5, 2026 | theglobeandmail.comKiora Pharmaceuticals Announces Management Team ChangesApril 2, 2026 | newsfilecorp.comNKiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical TrialsMarch 25, 2026 | newsfilecorp.comNKiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences ConferenceFebruary 19, 2026 | newsfilecorp.comNRetinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory BoardJanuary 27, 2026 | newsfilecorp.comNKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory CompoundsDecember 1, 2025 | finanznachrichten.deKiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory CompoundsDecember 1, 2025 | newsfilecorp.comNKiora Pharmaceuticals Reports Improved Financial PerformanceNovember 10, 2025 | tipranks.comKiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal DiseasesNovember 7, 2025 | newsfilecorp.comNKiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular DisordersOctober 30, 2025 | prnewswire.comKiora Pharmaceuticals Advances Phase II Study for Retinitis Pigmentosa TreatmentOctober 27, 2025 | tipranks.comKiora Pharmaceuticals Advances Promising Eye Treatment with KIO-301 StudyOctober 27, 2025 | tipranks.comKiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema?October 27, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCASI, CDT, APRE, and KPRX Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.86 +0.02 (+1.99%) As of 02:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.CASI Pharmaceuticals NASDAQ:CASI$0.21 0.00 (0.00%) As of 05/4/2026CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.CDT Equity NASDAQ:CDT$2.21 +0.13 (+6.30%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Kiora Pharmaceuticals NASDAQ:KPRX$2.52 +0.01 (+0.32%) As of 02:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
